Webdelics is excited to present the Top 25 Venture Capital and Institutional Investors shaping the future of psychedelics. These firms are actively supporting companies advancing mental health, therapeutics, and care delivery in this quickly evolving space. This list recognizes institutional investors with a firm commitment to the field, shares insights into where significant capital is being invested via each firm, and highlights who is driving the transition of psychedelic medicine from early-stage concepts to real-world applications.
Areas of Investment Focus
Health & wellness, positive healthy living, and behavior/mental-health outcomes. Able Partners specifically invests around what they call “The Wellness Gap”; the delta between rising economic indicators and stagnating measures of physical and mental wellbeing.
Their Contribution to The Psychedelic Sector
Able Partners is an early-stage venture fund that invests in companies improving daily health and wellbeing. They explicitly frame therapeutic psychedelics as a way to narrow The Wellness Gap, and they’ve backed major public leaders in the category, as listed below. Founded in 2016 by Lisa Blau and Amanda Eilian, the fund has grown to over 80 portfolio companies and has produced notable exits in tech including Spring Health, Bumble, and BlockFi.
Psychedelic Investments (publicly disclosed)
COMPASS Pathways (participated in the $80M Series B)
Atai Life Sciences
Journey Clinical (psychedelic-assisted therapy platform; participated in $8.5M Series A)
Osmind
Typical Check Size
Seed–Series B
Areas of Investment Focus
Psychedelic therapies and technologies, mental health innovation, and early-stage frontier healthcare companies.
Their Contribution to The Psychedelic Sector
Ambria Capital is one of the most psychedelic-native investment firms in the market, with an explicit thesis centered on psychedelic-assisted therapies as the next major innovation in mental healthcare. Founded in 2018 by Michael Sobeck (also the founder of the Perception Restoration Foundation, a nonprofit dedicated to HPPD treatment), Ambria manages its own capital, giving the firm the freedom to fund companies at any stage, in any amount, for as long as it takes. The team has backed 20+ psychedelic companies and 50+ companies overall. Ambria’s president, Cody Shandraw, was recognized as the 2021 Investor of the Year at the inaugural Microdose Awards, and is a frequent voice at leading industry conferences. Because Ambria self-funds rather than raising from LPs, it operates with unusual flexibility and long-term conviction in the sector.
Psychedelic Investments (publicly disclosed)
CybinField TripEleusisAwakn Life SciencesMindset PharmaGilgameshBionomicsBexon BiomedicalClairvoyantDiamond TherapeuticsHeadingPsychedelic WaterMindcureRevitalistOcean BiomedicalMycrodoseWesana HealthGwellaAtai Life SciencesSmall PharmaNote: Ambria’s portfolio includes 20+ psychedelic companies. Additional investments span public and private markets across clinical, manufacturing, and commercial psychedelic categories. The above reflects companies independently verifiable through press releases, databases, and the firm’s own disclosures.
Typical Check Size
Pre-Seed to Series A (range $100K–$5M). Also active in public-market and crossover-style exposures.
.png)
Areas of Investment Focus
Multi-strategy investing in technology and life sciences aimed at longer, healthier, more fulfilling lives.
Their Contribution to The Psychedelic Sector
Apeiron (Christian Angermayer’s family office and private investment firm) is one of the most influential capital allocators in modern psychedelic medicine, with deep, long-horizon conviction in the category. Angermayer is widely credited with leading the current psychedelic renaissance. He co-founded Atai Life Sciences in 2018 and provided the initial seed investment (~£3M) to COMPASS Pathways in 2017. Apeiron manages more than USD $2.5 billion across offices in London, New York, Abu Dhabi, and Berlin. Apeiron also launched re.Mind Capital as its dedicated mental health venture arm (with partners Jan Hardorp and Max de Vere), which has made additional psychedelic-adjacent investments.
Psychedelic Investments (publicly disclosed)
Atai Life Sciences (co-founded by Angermayer; Apeiron holds approximately a 22–23% stake as anchor shareholder, based on the latest public documents)COMPASS Pathways (early seed backer & held ~28% stake at IPO)
Typical Check Size
Not publicly standardized (multi-strategy; private + public; deal-specific).
Areas of Investment Focus
Mental health, psychedelics, neuroscience, and longevity-oriented healthcare innovation.
Their Contribution to The Psychedelic Sector
Ayuh Ventures is an early-stage fund with an explicit commitment to psychedelics as a next-generation mental health category. Their investments are anchored in high-signal psychedelic therapeutics and infrastructure plays, spanning drug development and clinical trial enablement. They also publish detailed fund commentary that clarifies how they underwrite psychedelic science as “FDA-grade neuro meds,” not just for lifestyle of health and wellness.
Psychedelic Investments (publicly disclosed)
Beckley PsytechClerkenwell HealthGilgamesh PharmaceuticalsMindstate Design LabsReset PharmaSamphire NeuroscienceKadence BioPsy TherapeuticsPepper BioLief Therapeutics
Typical Check Size
Pre-Seed+ through Series A/B; check size not publicly standardized/disclosed.
Areas of Investment Focus
Neuroscience, brain health, and what XEIA calls "Human 3", the convergence of life sciences, AI, hardware, software, deep tech, and health tech to elevate human health, wellbeing, and performance. Within this thesis, psychedelic medicine is a core investment vertical alongside brain-computer interfaces, neuromodulation, genetic medicine, and longevity.
Their Contribution to The Psychedelic Sector
XEIA Venture Partners (formerly Empath Ventures / Focal Point) has evolved from a dedicated psychedelics-focused seed investor into a broader neuroscience and "Human 3" platform, although psychedelic medicine remains a meaningful part of its portfolio. The firm has backed companies spanning the full psychedelic value chain: novel molecule design (Mindstate), MDMA-assisted therapy (Resilient Pharmaceuticals), ibogaine treatment delivery (Beond), ketamine therapeutics (Freedom Biosciences), and psychedelic-assisted therapy access/benefits infrastructure (Tara Mind). XEIA's $8M seed investment in Tara Mind alongside Satori Neuro is particularly notable as an example of psychedelic-ecosystem cross-pollination among funds on this list. The firm's broader neurotech portfolio (BCIs, neuromodulation, genetic medicine) also positions it at the frontier of where psychedelic science meets next-generation brain health.
Psychedelic Investments (publicly disclosed)
Mindstate Design Labs
Beond
Resilient Pharmaceuticals (formerly Lykos Therapeutics)
Freedom Biosciences
Tara Mind
Pepper Bio
Xylo
Note: XEIA's portfolio has evolved significantly from its earlier "Empath Ventures" branding. Previous reporting attributed investments in Wavepaths, Quantified Citizen, and Mycrodose Therapeutics to the firm, although these do not appear on the current XEIA portfolio page and may reflect earlier positions no longer actively held or displayed. The above list reflects the firm's current publicly visible portfolio.
Typical Check Size
Pre-seed to Seed; the firm also describes itself as an "accelerator" in addition to being a venture investor.
Areas of Investment Focus
Mission-driven, systems-change investing via Helena's for-profit investment arm (HSI), supporting category-defining solutions across major global challenges including climate, advanced technologies, public health, and governance.
Their Contribution to The Psychedelic Sector
Helena led the $100M+ oversubscribed Series A for MAPS PBC (renamed Lykos Therapeutics, now Resilient Pharmaceuticals) in January 2024, which was one of the largest single financings in the psychedelic therapeutics sector. Helena Managing Partner Protik Basu also joined the board as investor representative as the FDA declined to approve the MDMA-AT application in August 2024. A $50M Series B recapitalization in 2025 brought new leadership (Mike Burke as CEO, Javier Muniz as CMO) and a rebrand to Resilient Pharmaceuticals. Resilient continues pursuing FDA approval for MDMA-assisted therapy for PTSD and this is one of the most watched avenues right now in the psychedelic sector.
Psychedelic Investments (publicly disclosed)
Resilient Pharmaceuticals (formerly Lykos Therapeutics / MAPS PBC)
Typical Check Size
trategic lead capital for Series A and above.
Areas of Investment Focus
Venture fund focused on digital health, transformative therapies, consumer wellness brands, food system innovations, and mental health initiatives. Donates 10% of profits to its nonprofit arm, Reconsider.
Their Contribution to The Psychedelic Sector
Integrated is one of the most concentrated psychedelic-focused venture funds among generalist health/wellness investors. The fund led Beckley Psytech's oversubscribed $80M Series B in August 2021 (originally targeted at $50M), one of the largest private psychedelic therapeutics rounds at the time. Beckley Psytech subsequently merged with Atai Life Sciences in November 2025 to form AtaiBeckley N.V., a Phase 3-ready company whose lead asset BPL-003 (intranasal 5-MeO-DMT) met its primary endpoint in a Phase 2b trial for treatment-resistant depression. Integrated's broader portfolio of 11 companies includes multiple psychedelic and psychedelic-adjacent investments across drug development, provider infrastructure, and VR-based wellness.
Psychedelic Investments (publicly disclosed)
Beckley Psytech (led $80M fundraise)
MycoMedica Life Sciences
Frequency Breathwork
Small Pharma
Transcend
TRIPP
Homecoming
Typical Check Size
Early-stage focus all the way up to Series B (and beyond); not publicly standardized/disclosed.
Areas of Investment Focus
Early-stage alternative therapeutics for mental/behavioral health; psychedelic value-chain investing (APIs, drug development, clinics, and enabling infrastructure).
Their Contribution to The Psychedelic Sector
Iter is a psychedelics-native VC that explicitly invests across the entire psychedelic value chain (not just molecules) spanning API suppliers, drug developers, clinics, and “rails” like education and research platforms. Founded by psychedelics attorney Dustin Robinson, they’ve built a sizable early portfolio (16 companies reported at Fund I close) and have positioned themselves as a funding-gap specialist for early-stage psychedelic innovation.
Psychedelic Investments (publicly disclosed)
Beckley Psytech (now AtaiBeckley)
Wesana Health
Awakn Life Sciences
PsyTech (acquired by Wesana in 2021)
TRIPP
Psilera
Nucleus Holding (parent of Psychedelic Invest and Neuly; founded by Iter)
Apex Labs
Clairvoyant Therapeuticsa
NUma
Reset Pharma
Quantified Citizen
Freedom Bio
Regenerative Financing MAPS/Vine SPV
Fluence
Muse
Sensorium Therapeutics
Beckley Retreats
Psygen
Typical Check Size
Seed–Series A; check size not publicly standardized/disclosed (Fund I closed with $20M+ committed).
.png)
Areas of Investment Focus
Neuroscience, mental health, psychedelic therapeutics, and enabling tools and infrastructure; positioned around neuromedicine and psychedelic-medicine exposure.
Their Contribution to The Psychedelic Sector
JLS Fund is a psychedelics-and-neuroscience-native VC formed in 2019 to invest at the intersection of science, technology, and neurology. Led by managing partners Lindsay Hoover, Jeffrey Siegel, and Simeon Schnapper, the fund deploys across the full psychedelic and brain-health value chain, from drug development and psychedelic-assisted therapy training to digital therapeutics, neurotech, and clinical infrastructure. PitchBook reports 33 investments and 11 exits. Fund I is deploying $50 million. JLS portfolio company Gilgamesh Pharmaceuticals was acquired by AbbVie in August 2025 in a deal worth potentially over $1 billion.
Psychedelic Investments (publicly disclosed)
Enthea
Psilera Bioscience
TRIPP
Gilgamesh Pharmaceuticals
Fluence
Homecoming
Psy Therapeutics
ProNovo
Typical Check Size
Pre-seed and Seed to Series A, plus later-stage secondaries transitioning to buyout; check size not publicly standardized/disclosed.
Areas of Investment Focus
Frontier technology, deep tech, and selective investments in breakthrough health and mental health companies.
Their Contribution to The Psychedelic Sector
KittyHawk is a frontier-tech venture firm founded in 2015 by Will Weisman (former Executive Director of Singularity University), focused on seed to late-stage pre-IPO companies across AI, computing, aerospace, longevity, climate, and healthcare. Its psychedelic exposure is limited but very intentional, as KittyHawk co-led the $60M Series A for MycoMedica Life Sciences (psilocybin drug development, founded by Paul Stamets), participated in the $100M+ Series A for Resilient Pharmaceuticals (formerly Lykos Therapeutics / MAPS CorPBC), and invested in Progressive Therapeutics (low-dose ketamine therapeutics for women's health, founded by Phil Wolfson) via Fund III.
Psychedelic Investments (publicly disclosed)
MycoMedica Life Sciences
Resilient Pharmaceuticals (formerly Lykos Therapeutics / MAPS PBC)
Progressive Therapeutics
Typical Check Size
Seed-stage through growth follow-ons (frontier strategy; deal-specific)
Areas of Investment Focus
Psychedelic therapeutics, drug discovery, care delivery, and ecosystem infrastructure.
Their Contribution to The Psychedelic Sector
Leafy Tunnel is a London-based early-stage VC investing across both medical cannabis and psychedelic therapeutics, the first fund of its type approved in Guernsey. Co-founded in 2020 by Nikolay Tretiyakov and Bek Muslimov, with Andrey Makiyevskiy as Principal, Fund 1 targets $30M and up to 15 companies. Its psychedelic portfolio is concentrated but includes participation in Beckley Psytech's oversubscribed $80M Series B alongside an investment in Tactogen (MDMA analogues, first U.S. patent for novel MDMA derivatives) and Maya Health (psychedelic practitioner software). The remainder of the fund's portfolio is European medical cannabis.
Psychedelic Investments (publicly disclosed)
Beckley Psytech (now AtaiBeckley)
2A Biosciences
Resilient Pharmaceuticals (formerly Lykos Therapeutics / MAPS PBC)
Tactogen
Maya Health
Typical Check Size
Early-stage (Seed to Series A; syndicate-style participation common)
Areas of Investment Focus
Artificial intelligence and frontier mental health technologies, including psychedelic medicine and neuromodulation.
Their Contribution to The Psychedelic Sector
Lionheart Ventures is a seed-stage VC firm founded in 2019, focused on AI and frontier mental health. Founded by David Langer (founder of Zesty, acquired by Square) with Partner Shelby Clark (founder of Turo). The firm has deep psychedelic domain expertise: Venture Partner Amy Emerson is the founding CEO of Lykos Therapeutics and sits on the Board of Resilient Pharmaceuticals; Principal Armin Khayatian was formerly Director of Business and Corporate Development at Compass Pathways; Principal Milan Griffes co-founded Atman, a psychedelic retreat (acquired by Odyssey in 2024); and the extended team includes psychedelics advisors Dr. Joseph Barsuglia, Josh Hardman (founder of Psychedelic Alpha), Liana Sananda Gillooly (formerly MAPS), and Dr. Gregory Wells (co-PI for MAPS MDMA Phase III trials). PitchBook reports 63 total investments across both AI and mental health funds, with 13 exits. Of the 48 current portfolio companies on their website, at least 18 are psychedelic-sector.
Psychedelic Investments (publicly disclosed)
2A Biosciences
Clerkenwell Health
Dimensions
Mindstate Design Labs
Entheos Labs
Homecoming
TRIPP
Wavepaths
Woven Science
Reconnect Labs
Journey Clinical
Meeko Health
Bexson Biomedica
lJourney Colab
Luminous Mind
Resilient Pharmaceuticals (formerly Lykos Therapeutics / MAPS PBC)
Progressive Therapeutics
Tactogen
Xylo
Note: Lionheart has made additional psychedelic and mental-health-adjacent investments beyond this list. The firm reports over 50 total investments across its funds (including AI). The above reflects investments independently verifiable through press releases, job postings, and third-party databases.
Typical Check Size
Early-stage (Pre-Seed to Seed; $100K–$5M)
Areas of Investment Focus
Mystic Ventures describes itself as an early-stage biotechnology venture fund focused on seed and pre-seed companies in psychedelic medicine and consciousness expansion, with three stated pillars: Pharmaceuticals, Clinical Infrastructure, and Digital Therapeutics.
Their Contribution to The Psychedelic Sector
Mystic Ventures is led by Jeremy Gardner (Founder), who states he launched Mystic Ventures in late 2021 to focus on psychedelic medicine. The fund’s published thesis frames psychedelic therapies, combined with precision neuromedicine and machine learning, as a near-term wave of transformative tools, and positions Mystic’s mandate at the intersection of biotechnology, AI, and longevity, with an explicit ambition to “elevate consciousness at scale.” Mystic operationalizes that philosophy across its stated pillars (novel compounds, delivery infrastructure, and technology-enabled therapeutic experiences), while publicly disclosing a diversified portfolio across therapeutic development, care infrastructure, and psychedelic-adjacent platforms.
Psychedelic Investments (publicly disclosed)
Lykos Therapeutics
2A Biosciences
Freedom Biosciences
Spiritus Bioscience
Stillmind Therapeutics
Xylo Bio
Mindstate Design Labs
Next Life Sciences
Psilera
Equulus Therapeutics
Journey Clinical
Heading Health
Maya Health
Enthea
Psychedelic Water
Supermush
Breathwrk
Nana Health
Bia Neuroscience
Hatch
Sempera Organics
CB Therapeutics
Beckley Retreats
HolosWake Network
DopaGe
Double Blind
Sama Therapeutics
Firefly VR
Soundself
Nucleus
Adamo Bioscience
Typical Check Size
Pre-seed / Seed (early-stage focus)
Areas of Investment Focus
Biotech and therapeutics, including neuropsychiatry and emerging mental health treatments.
Their Contribution to The Psychedelic Sector
Negev Capital positions itself as a psychedelic medical intervention fund focused on psychedelic-compound-based neuropsychiatric drug development, with $30M+ reported fund size and typical $500K–$2M initial equity checks. The firm explicitly targets preclinical and Phase I programs and publicly highlights multiple psychedelic-therapeutics case studies and portfolio logos on its website. Its participation in notable financings (e.g., Gilgamesh’s Series B) provides independent corroboration of real deployment into the psychedelic therapeutics stack.
Psychedelic Investments (publicly disclosed)
Bright Minds Biosciences
Atai Life Sciences
Psylo (dba Xylo Bio)
Awakn Life Sciences
BetterLife Pharma
BioMind
Filament Health
MindBio Therapeutics
Cybin
Delix Therapeutics
Reset Pharma
Freedom Biosciences
Beckley Psytech
Gilgamesh Pharmaceuticals
Small Pharma
Compass Pathways
Mindset Pharma
Mindstate Design Labs
Psyched Wellness
Reconnect Labs
Typical Check Size
Early biotech (Preclinical to Phase 1; deal-specific)
Areas of Investment Focus
Mental health innovation, psychedelic care infrastructure, digital therapeutics, and clinics/care delivery.
Their Contribution to The Psychedelic Sector
Neo Kuma Ventures was formed in 2019 by Sean McLintock, Clara Burtenshaw, and Nick David, and launched publicly in December 2020 as the UK’s first investment fund devoted to psychedelic healthcare. Neo Kuma positions itself as an early-stage specialist “funding the future of psychedelic healthcare,” backing science-led teams and aiming to “advance and redefine the standard of patient care.” The firm’s approach is explicitly ecosystem-driven, stating it provides “more than just capital” and works with partners like Drug Science and the International Therapeutic Psilocybin Rescheduling Initiative to help shape research and policy tailwinds.
Psychedelic Investments (publicly disclosed)
Atai Life Sciences
Beckley Psytech
Bright Minds
Small Pharma
Journey Clinical
Sana Health
Wavepaths
Solvonis Therapeutics
Monument Therapeutics
Tripp
Neurocentrx
Typical Check Size
Pre-Seed to Series A (reported range varies by deal)
.png)
Areas of Investment Focus
Neuroscience, mental health, psychedelic therapeutics, and supporting care platforms. Noetic’s diversified, multi-modal strategy spans novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, wearables and other evidence-backed solutions.
Their Contribution to The Psychedelic Sector
Noetic Fund is one of the most important specialist investors in the psychedelics ecosystem, launched through Grey House Partners in Toronto. Led by Managing Partners Sa'ad Shah and Warren Wright, the fund invests globally in early-stage CNS-targeted therapeutics and related solutions. Fund I produced multiple IPO exits including COMPASS Pathways, Cybin, MindMed, and Numinus, plus the Eleusis exit (acquired by Beckley Psytech, now AtaiBeckley). Fund II led the $22M Series A for CaaMTech and the $7.2M seed for the Alexander Shulgin Research Institute. Portfolio company Gilgamesh Pharmaceuticals was acquired by AbbVie in August 2025 in a deal worth potentially over $1 billion. PitchBook reports 33 total investments and 11 exits across both funds.
Psychedelic Investments (publicly disclosed)
Cybin (exited via IPO)
Beckley Psytech (now AtaiBeckley
Psygen
CaaMTech (led $22M Series A via Fund II)COMPASS Pathways (exited via IPO)
MindMed (exited via IPO)Delix Therapeutics
PsyBio Therapeutics
Bexson Biomedical
Alexander Shulgin Research Institute / ASRIDAMONA Pharmaceuticals
Diamond Therapeutics
Eleusis (exited; acquired by Beckley Psytech)
Gilgamesh Pharmaceuticals (lead asset acquired by AbbVie in 2025)
Woven Science
Numinus (exited via IPO)
People Science
Tactogen
WakeTerran Biosciences
Typical Check Size
Early-stage to growth follow-on (Seed through later private rounds; fund-dependent)
Areas of Investment Focus
Psychedelic medicine, mental health, breakthrough CNS therapeutics, and supporting ecosystem companies across biopharma, drug development, digital therapeutics, and healthcare services.
Their Contribution to The Psychedelic Sector
Palo Santo is one of the best-known and most active dedicated psychedelic investment firms. Co-founded in 2020 by Daniel Goldberg, Tim Schlidt, and Tony Eisenberg, the firm closed an oversubscribed $50M fund in October 2022 and has built a portfolio of 26+ companies. Palo Santo has played a prominent role in shaping the sector’s private capital ecosystem and is widely referenced by founders and industry analysts as a specialist with deep domain focus and long-term conviction in psychedelic medicine. The fund is further supported by a distinguished scientific advisory board including leading serotonin 2A researchers Charles D. Nichols, PhD and John D. McCorvy, PhD.
Psychedelic Investments (publicly disclosed)
GilgameshJourney Clinical
Atai Life Sciences
2A Biosciences
Beckley Psytech
Reset Pharma
Sensorium Therapeutics
Bexson Biomedical
Xylo Cybin
Bright Minds
Tactogen
Delix Therapeutics
Blackbox Bio
Diamond Therapeutics
Eleusis
PSY Therapeutics
Reunion Neuroscience
Syndeio Biosciences
Field Trip Health
Fluence
Kanna Health
MycoMedica Life Sciences
neuroCare
Pangea BioT
ranscend Therapeutics
Note: Palo Santo’s portfolio includes 26+ companies. Additional investments not enumerated here due to inability to confirm all investments in fund.
Typical Check Size
Early-stage to growth (Seed through later private rounds; sector specialist)
Areas of Investment Focus
Psychedelic therapeutics, clinics/care delivery, digital support tools, and ecosystem infrastructure.
Their Contribution to The Psychedelic Sector
Phyto Partners’ Psyche Fund is led by Larry Schnurmacher (Managing Partner) and Cody Shandraw (Managing Partner), with Aaron Raub (Senior Analyst) listed on the fund’s official page. The firm frames its psychedelics strategy around three explicit pillars: therapeutics developers, research tools/organizations, and ancillary companies supporting the growth of the psychedelics industry. Their posture is thesis-driven and ecosystem-oriented, specifically emphasizing deep diligence and operational networks in a sector where they note information can be “sparse and unreliable.” Unlike many managers who keep company holdings opaque, Phyto publishes a compact Psyche portfolio on its official site, enabling direct verification of its current disclosed exposure.
Psychedelic Investments (publicly disclosed)
Wonder SciencesHealing MapsMindstate Design LabsHealing Commercial REITFirefly NeuroscienceWondermed
Typical Check Size
Early-stage (Pre-Seed to Series A; sector-focused)
Areas of Investment Focus
Psychedelic therapeutics, mental health innovation, biotech, and related care ecosystem infrastructure.
Their Contribution to The Psychedelic Sector
PsyMed Ventures is co-founded by Matias Serebrinsky and Greg Kubin, with Dina Burkitbayeva also listed as a Co-Founder. The firm frames its mission as funding founders “elevating brain and mental health” while aligning healing, responsibility, and profitability. Within a broader frontier-neuroscience mandate, PsyMed explicitly includes “Psychedelic Medicine & New Compounds” as a dedicated investment focus area. Their model is unusually transparent for an early-stage operator and they openly publish an on-site investments list that spans psychedelic drug development and the therapy-enablement stack.
Psychedelic Investments (publicly disclosed)
Delix Therapeutics
Atai Life Sciences
Mindstate Design Labs
Beckley Psytech
Tactogen
TRIPP
Bexson Biomedical
Sanmai
Bright Minds
Freedom Biosciences
Journey Clinical
Maya Health
Reset Pharma
Gilgamesh PharmaceuticalsTerran
Typical Check Size
Early-stage to Series A/B follow-on (sector-focused; deal-specific)
Areas of Investment Focus
Brain and mental health innovation across therapeutics, neurotechnology, and scalable care models.
Their Contribution to The Psychedelic Sector
Satori Neuro is Satori Capital’s mental-health strategy focused on “human flourishing,” led by Chief Investment Officer Dr. Amy Kruse, and built to invest across the broader brain/mental-health ecosystem rather than a single modality. Within that mandate, Satori Neuro has explicit, publicly visible psychedelic exposure, focusing on the entire ecosystem of development. Kruse is also an active public voice in the category and has been cited by Psychedelic Alpha regarding their psychedelic/psychiatric drug development momentum, reinforcing that psychedelics are a deliberate (not an incidental) part of the strategy’s opportunity set.
Psychedelic Investments (publicly disclosed)
Beckley Waves
Entheos Labs
Lykos PBC
Soneira
Sunstone
Typical Check Size
Early-stage to growth (mental health strategy; deal-specific)
.png)
Areas of Investment Focus
Public and private opportunities in emerging sectors, including cannabis and psychedelic mental health platforms.
Their Contribution to The Psychedelic Sector
Subversive Capital (led by Michael Auerbach) was one of the earlier mainstream investors to place visible bets in the psychedelics market cycle, especially through platform and clinic plays. Its role as the lead investor in Atai Life Sciences’ $43M Series B (the largest private financing round for a psychedelic medicine company at the time) and subsequent participation in Atai’s $157M Series D gives it outsized historical relevance to the sector’s capital formation story.
Psychedelic Investments (publicly disclosed)
Atai Life Sciences
Field Trip Health
Typical Check Size
Flexible (private venture and public-market exposure; deal-specific)
Areas of Investment Focus
Mental health, psychedelic therapeutics, neurotechnology, and care delivery platforms.
Their Contribution to The Psychedelic Sector
The Conscious Fund positions itself as a specialist early-stage investor in psychedelic medicine, explicitly framing its mandate around improving outcomes for mental health, addiction, and pain. Co-founder and managing partner Henri-Sant Cassia is publicly featured in the fund’s own content and marketing efforts, along with industry events. The firm differentiates itself through unusually visible public disclosure via its official Portfolio page providing investors with stage/status context and SPV flags, enabling direct diligence by founders and LPs.
Psychedelic investments (publicly disclosed)
Albert Labs
Bexson Biomedical
BrainFutures
Calyx
Clearmind Medicine
Delix Therapeutics
Gilgamesh Pharmaceuticals (lead asset acquired by AbbVie in 2025)
H. Transcend
KIIRA
Neuroelectrics
Nia Therapeutics
Nue Life
Osmind
Typical Check Size
Early-stage (Pre-Seed to Series A; specialist fund participation)
Areas of Investment Focus
Conscious health and wellness, psychedelic ecosystem development, and ethical/scalable mental health innovation.
Their Contribution to The Psychedelic Sector
Vine Ventures is one of the most culturally influential investors in the psychedelic ecosystem, pairing capital with a strong public thesis around ethical industry building, founded by Ryan Zurrer, with team members Ozan Polat and Robbie Bent (co-founder/CEO of Othership). Vine commits 50% of GP carry to non-profit mental health initiatives via its Entrepreneur's Reciprocity Pledge. The fund co-created the Regenerative Financing Vine (RFV) with MAPS, a $70M social impact SPV to fund patient access infrastructure and research for MDMA-assisted therapy. Vine invests across both company formation and the broader ecosystem infrastructure shaping psychedelic care.
Psychedelic Investments (publicly disclosed)
Gilgamesh Pharmaceuticals (lead asset acquired by AbbVie in 2025)PsygenTRIPPResilient Pharmaceuticals (formerly Lykos Therapeutics; confirmed Series A investor)
Typical Check Size
Early-stage (inception to Seed; follow-through participation possible)
Areas of Investment Focus
Early-stage frontier and world-changing technologies, including mental health and psychedelic opportunities.
Their Contribution to The Psychedelic Sector
What If Ventures has shown willingness to back early psychedelic and consciousness-oriented companies while maintaining a broader frontier-tech lens. What If Ventures is led by founder and managing partner Stephen Hays, who positions the firm as a “what if?”- driven investor in radically transformative technologies with a strong emphasis on Disruptive Healthcare. The fund describes itself as stage-agnostic with flexible check sizes, signaling a mandate built around conviction and adaptability rather than a single-stage playbook. Within that broader frontier lens, What If’s published portfolio includes multiple bets at the intersection of mental health and psychedelic therapeutics.
Psychedelic investments (publicly disclosed)
2A Biosciences
Atai
Beckley Psytech
Field Trip
Gilgamesh
Mindbloom
Psilera
TRIPP
atai Life Sciences
Typical Check Size
Early-stage (Seed; selective follow-on)
Areas of Investment Focus:
Venture creation and early-stage science platforms in brain health, mental health, and next-generation therapeutics.
Their Contribution to The Psychedelic Sector
Woven Science is a psychedelic-focused holding company and venture studio co-founded in 2020 by Nick von Christierson, Giles Hayward, and Louis Sagar, headquartered in New York City. The platform builds, backs, and incubates companies across the entire psychedelic treatment arc through three pillars: Woven Labs (drug development and health tech), Woven Wellness (plant-medicine product development and distribution), and El Puente (nonprofit arm promoting access and benefit-sharing with indigenous peoples). Woven raised an oversubscribed $8.5M seed round led by Noetic Fund, with participation from Lionheart Ventures, London Impact Ventures, and Anya Capital. Per Psychedelic Finance, the portfolio spans 9 drug development companies across 5 compounds (psilocybin, 5-MeO-DMT, DMT, ketamine, MDMA) in 4 countries, plus health tech and accelerator companies. Woven partnered with Founders Factory to launch the first psychedelic and mental wellness accelerator program.
Psychedelic Investments (publicly disclosed)
Beckley Psytech
Cybin
Mindstate Design Labs
Reconnect LabsTactogen
Bright Minds
Bexon Biomedical
Luminous Minds
MayaThe Medicinal Mushroom Co
Note: Woven Science's website displays approximately 31 company logos across its three pillars, but does not publicly enumerate portfolio companies by name. Per Psychedelic Finance and Blossom Analysis, the full portfolio includes approximately 17 companies spanning drug development, health tech, accelerator, wellness products, and indigenous initiatives. Only companies confirmable through press releases or verified third-party announcements are listed above.
Typical Check Size
Seed to Series A (venture studio / builder model; deal-specific)
This list focuses on high-impact investment firms and funds with verifiable psychedelic-related investments and a repeatable thesis in psychedelic medicine and/or the infrastructure that enables it (therapeutics, care delivery, research tooling, access platforms).
We intentionally did not include individual angel investors or public personalities (even well-known ones like Tim Ferriss) because the goal is to map the institutional capital landscape, not individual check-writers, although it should be acknowledged that individual check-writers are essential for this ecosystem to survive and grow.
Firms were excluded when psychedelic exposure couldn’t be confirmed through reliable public sources, when involvement appeared purely incidental, or when portfolio information was too opaque to support publication-grade accuracy.
Note: Lykos Therapeutics (formerly MAPS Public Benefit Corporation / MAPS PBC) has since rebranded to Resilient Pharmaceuticals. All references in this document reflect the most current names, as well as we can research.
Also of note: AbbVie acquired Gilgamesh Pharmaceuticals’ lead asset (bretisilocin/GM-2505) in August 2025 in a deal worth potentially over $1 billion, a landmark exit for the psychedelic therapeutics sector that touched many of the investors profiled below.
